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LETTERS TO THE EDITOR
Pemetrexed-Induced
Fluid Retention
To the Editor:
Despite the favorable toxicity and
safety profiles of pemetrexed (Alimta;
Eli Lilly and Company, Indianapolis,
IN), several adverse events have been
reported, including blood and lymphatic
system disorders, gastrointestinal disor-
ders, and general disorders.1–3 In this
letter, we describe a case series consisting
of seven patients who developed clinically
significant fluid retention, an uncommon
adverse effect associated with the use of
pemetrexed. All patients have received vi-
tamin supplementation and were pre-
treated with corticosteroids as indicated in
the package insert (Table 1).
Other causes of edema were ex-
cluded, and all patients had normal
echocardiogram, normal levels of
B-type natriuretic peptide and albumin,
normal renal, hepatic, and thyroid func-
tion tests, and no significant proteinuria.
Most patients presented with mild-to-
moderate edema, mainly in periorbital
area, as illustrated in Figure 1 (case 1).
Of the seven cases, only one patient
(case 4) developed grade 3 refractory
edema with symptomatic bilateral effu-
sion. A bilateral thoracocentesis was
necessary for symptom relief, and the
pleural effusion analysis was consistent
with an exudate with no malignant cells
and negative cultures. There was com-
plete disappearance of generalized
edema and bilateral pleural effusion af-
ter discontinuation of pemetrexed treat-
ment. Another patient (case 6) also had
complete resolution of the edema after
pemetrexed was discontinued because
of disease progression. All other cases
were managed with observation only or
salt restriction and diuretics, with lim-
ited control of this side effect. Because
of sustained partial responses and dis-
ease control, treatment with pemetrexed
was continued in all but one patient,
which was described above, despite the
incomplete control of this problem.
Pemetrexed-associated peripheral
and eyelid edema has been rarely re-
ported, with an estimated incidence of
1% in clinical trails.1,4 To our knowl-
edge, there were no severe cases re-
ported with need for treatment discon-
tinuation until now. The mechanism
involved in the development of fluid
retention and consequent edema is un-
known, but may be because of capillary
leakage syndrome.4 Now that pem-
etrexed has demonstrated efficacy in the
first-line setting and is an option as
maintenance or early second-line ther-
apy, more patients will be exposed to
this agent, and therefore more individu-
als will potentially develop this treat-
ment-related adverse effect. Therefore,
we believe it is important to report this
unusual adverse event and to understand
its pathophysiology to attempt to de-
velop strategies to avoid and manage
this uncommon side effect.
Diogo Assed Bastos, MD
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Safety of Concomitant
Administration of
Seasonal and/or H1N1
Flu Vaccination in
Patients Receiving
Erlotinib for Advanced
Non-small Cell Lung
Cancer
To the Editor:
Patients with advanced tumors are
at higher risk of acquiring and dying
from infections, because of a weaker
immune system, among other factors.1
For this reason, Centers for Disease Con-
trol and Prevention guidelines strongly
recommend flu vaccination in cancer
patients older than 50 years. More-
over, the pandemic distribution of
H1N1 virus led to the preparation of
new vaccines, which should be used in
this setting.2
Patients with advanced non-small
cell lung cancer (NSCLC) are often ad-
equate candidate for flu vaccination be-
cause of chronic respiratory disease, ad-
vanced age, and poor performance
status. Efficacy of H1N1 influenza vac-
cination in this subgroup of patients
seemed to be comparable with that from
healthy volunteers.3 Although safety and
immunogenity of influenza vaccines in
patients receiving chemotherapy have
been extensively investigated, no data
on safety of vaccines in patients with
NSCLC treated with epidermal growth
factor receptor tyrosine kinase inhibitors
are available.
Epidermal growth factor receptor
tyrosine kinase inhibitors (erlotinib and
gefitinib) display the broadest spectrum
of adverse effects on skin and hair, in-
cluding folliculitis, paronychia, facial
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hair growth, facial erythema, and sev-
eral forms of frontal alopecia. On the
other hand, the most common influenza
vaccine side effects are tenderness and
pain in the site of injection. For this
reason, in the suspect that the concomi-
tant administration of erlotinib and sea-
sonal and/or H1N1 vaccination could be
burdened by severe reactions, we de-
cided to analyze the incidence of local
and systemic side effects in our series.
So far, we evaluated 14 patients
treated with erlotinib for advanced
NSCLC who received 11 administra-
tions of seasonal vaccine (Fluarix;
GlaxoSmithKline Biologicals, Rixen-
sart, Belgium) and seven of H1N1 vac-
cine (Focetria; Novartis, Inc., Basel,
Switzerland). Data were collected in a
median time of 30 days (range, 15–45
days) from vaccination by telephone in-
terviews to avoid the omission of unso-
licited reports.
All patients were receiving erlo-
tinib (150 mg: 6 patients; 100 mg: 8
patients) since12 months (range, 1–32
months). Six patients had grade 1 skin
rash, one had alopecia grade 1, and one
had vaginal mucositis grade 1 before
vaccine administration.
Neither local nor systemic adverse
events were recorded after the vaccina-
tion, except for one patient who referred a
grade 1 pain in the site of injection lasting
for 1 day and for another who had skinFIGURE 1. Facial and periorbital edema.
TABLE 1. Patients Characteristics
Case
Age
(yr) Sex Comorbidities Regimen
No. of Cycles
at Edema
Onset
Edema
Localization Gradea
Edema
Treatment
Continued
on
Pemetrexed
Actual
Treatment
1 61 F None Carboplatin and pemetrexed
(first line)
7 Eyelid and ankle I No Yes Pemetrexed
maintenance
2 39 F None Pemetrexed (second line) 13 Generalized (facial,
peripheral, and
pleural effusion)
II Yes Yes Pemetrexed
3 70 M Hypertension, chronic
obstructive pulmonary
disease, and
pulmonary embolism
Carboplatin and pemetrexed
(second line)
13 Peripheral II Yes Yes Pemetrexed
maintenance
4 63 M None Carboplatin, pemetrexed,
and bevacizumab
(first line)
14 Generalized (facial,
peripheral, and
pleural effusion)
III Yes No Erlotinib and
bevacizumab
5 47 F Depression Pemetrexed and bevacizumab
(third line)
16 Facial I No Yes Pemetrexed and
bevacizumab
6 74 M Diabetes Pemetrexed and bevacizumab
(second line)
6 Peripheral II Yes No —
7 49 F None Pemetrexed and bevacizumab
(second line)
8 Ankle I No Yes Pemetrexed and
bevacizumab
a Common Terminology Criteria for Adverse Events v 3.0 (CTCAE).
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rash grade 1 to lower limbs after 10 days.
Immunogenicity was not assessed. None
of the patients developed influenza.
In conclusion, we did not observe
any relevant toxicity in patients with
NSCLC treated with concomitant influ-
enza vaccination and erlotinib. Although
influenza vaccines are not devoid of
risk, these data could assure clinicians
and patients that they are safe for this
subset of patients.
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Adjuvant Chemotherapy
in New Stage II pN0
Non-small Cell Lung
Cancer: A New Issue for
a Case-By-Case Decision
Making Process
To the Editor:
The seventh edition of the tumor,
node, metastasis (TNM) classification1
has raised some new issues in the adjuvant
chemotherapy decision-making process.
Previously, pN0 tumors 5 cm
were classified as stage Ib. In the new
classification, they become stage IIa
(5 but 7 cm) or stage IIb (7 cm)
because of a poorer prognosis than
smaller pN0 tumors.
According to this observation and
consistent with the Cancer-Care-Ontario
Program and the American Society of
Clinical Oncology guide-lines (based on
the sixth TNM edition),2 patients with
new stage II pN0 disease should be
informed on their prognosis, and adju-
vant chemotherapy could be proposed as
an individual option.
This issue should be carefully dis-
cussed for a case-by-case decision, ac-
cording to the available information. In
the absence of evidence-based data, we
underline the lack of definitive informa-
tion on the effect of adjuvant chemother-
apy in patients with pN0 nonsmall cell
lung cancer (NSCLC), irrespective of tu-
mor size.
As a matter of fact, this is true not
only for patients with sixth TNM stage Ib
tumors but also for patients with sixth
TNM pT3 pN0 disease. Although the lat-
ter population was gathered together with
patients with T1–T2 pN1 disease in stage
II and, so, considered for adjuvant chemo-
therapy according to ASCO guidelines, a
critical appraisal to this topic from an
extensive review of the literature showed
the absence of evidence-based data on the
efficacy of adjuvant chemotherapy for
sixth TNM pT3 pN0 tumors.3
Nevertheless, data from the CALGB
9633 phase III randomized trial should
also be shared with the patient. This trial
did not observe a significant survival ad-
vantage in patients with sixth TNM stage
Ib NSCLC, but it was underpowered to
answer this question in the population of
new stage II pN0 tumors, i.e., 5 cm.
Interestingly, in the subgroup of patients
with 4 cm disease (196 patients: 99
patients in the treatment arm and 97 pa-
tients in the control arm), there were a
significant advantage in overall survival
(hazard ratio: 0.69, 90% confidence in-
terval: 0.48–0.99) and disease-free
survival (hazard ratio: 0.69, 90% con-
fidence interval: 0.49–0.97).4
The lack of data in pT3 pN0 tumors
and the shift from stage I to stage II of
patients with 5 cm pN0 NSCLC raise
the need for information on the effects of
adjuvant chemotherapy in this subset of
patients. Major efforts to run a prospective
phase III trial to answer this question and
to select the subset of patients with higher
probability to benefit from this treatment
(if any) are warranted.
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A Systematic Review
but Systematically
Confounded?
To the Editor:
The study by Nair et al1 on the
prognostic value of positron emission to-
mography (PET) intensity in stage I non-
small cell lung cancer (NSCLC) is a su-
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